Literature DB >> 24495184

Roles of Coagulation and fibrinolysis in angiotensin II-enhanced microvascular thrombosis.

Elena Y Senchenkova1, Janice Russell, Charles T Esmon, D Neil Granger.   

Abstract

OBJECTIVE: AngII-induced HTN is associated with accelerated thrombus development in arterioles. This study assessed the contributions of different components of the coagulation cascade and fibrinolysis to AngII-mediated microvascular thrombosis.
METHODS: Light/dye-induced thrombus formation (the time of onset and flow cessation) was quantified in cremaster muscle arterioles of AngII infused (two weeks) WT/AngII mice, EPCR-TgN, and mice deficient in PAI-1. WT/AngII mice were also treated with either tissue factor antibody, antithrombin III, heparin, hirudin, or murine APC.
RESULTS: TF immunoblockade or hirudin treatment did not prevent the AngII-induced acceleration of thrombosis. While antithrombin III treatment prevented the acceleration in both thrombus onset and flow cessation, heparin only improved the time for blood flow cessation. Neither WT mice treated with murine APC nor EPCR-TgN were protected against AngII-induced thrombus development. A similar lack of protection was noted in PAI-1deficient mice.
CONCLUSION: These findings implicate a role for thrombin generation pathway in the accelerated thrombosis induced by AngII and suggest that an impaired protein C pathway and increased PAI-1 do not make a significant contribution to this model of microvascular thrombosis.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  angiotensin II; anticoagulants; coagulation; fibrinolysis; thrombosis

Mesh:

Substances:

Year:  2014        PMID: 24495184      PMCID: PMC4107144          DOI: 10.1111/micc.12120

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  45 in total

Review 1.  Thrombin generation assays: understanding how the method influences the results.

Authors:  Alisa S Wolberg
Journal:  Thromb Res       Date:  2006-08-22       Impact factor: 3.944

2.  Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral microvasculature.

Authors:  Mami Ishikawa; Eiichi Sekizuka; Noriyuki Yamaguchi; Hiromichi Nakadate; Satoshi Terao; D Neil Granger; Haruyuki Minamitani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-01-12       Impact factor: 4.733

Review 3.  Hypercoagulable states in cardiovascular disease.

Authors:  Mark Y Chan; Felicita Andreotti; Richard C Becker
Journal:  Circulation       Date:  2008-11-25       Impact factor: 29.690

4.  Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes.

Authors:  Meixia He; Xiaofan He; Qinzhi Xie; Fangping Chen; Shilin He
Journal:  Thromb Res       Date:  2005-06-13       Impact factor: 3.944

5.  Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model.

Authors:  Heiko Sorg; Johannes N Hoffmann; Michael D Menger; Nicole Lindenblatt; Peter Goehring; Brigitte Vollmar
Journal:  Thromb Haemost       Date:  2006-09       Impact factor: 5.249

6.  Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis.

Authors:  Yuko Izuhara; Satoru Takahashi; Masaomi Nangaku; Shunya Takizawa; Hideyuki Ishida; Kiyoshi Kurokawa; Charles van Ypersele de Strihou; Noriaki Hirayama; Toshio Miyata
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-31       Impact factor: 8.311

7.  Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis.

Authors:  Hideo Yoshida; Janice Russell; Karen Y Stokes; Cigdem Erkuran Yilmaz; Charles T Esmon; D Neil Granger
Journal:  Gastroenterology       Date:  2008-04-22       Impact factor: 22.682

8.  Thrombin mediates the extraintestinal thrombosis associated with experimental colitis.

Authors:  Hideo Yoshida; Janice Russell; D Neil Granger
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-04       Impact factor: 4.052

9.  Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R.

Authors:  Anke Doller; Stefan Gauer; Ewelina Sobkowiak; Helmut Geiger; Josef Pfeilschifter; Wolfgang Eberhardt
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

10.  Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis.

Authors:  Yasushi Numaguchi; Masakazu Ishii; Ryuji Kubota; Yasuhiro Morita; Koji Yamamoto; Tadashi Matsushita; Kenji Okumura; Toyoaki Murohara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-10       Impact factor: 8.311

View more
  14 in total

1.  Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.

Authors:  Silvio Antoniak; Jessica C Cardenas; Laura J Buczek; Frank C Church; Nigel Mackman; Rafal Pawlinski
Journal:  Cardiology       Date:  2016-11-24       Impact factor: 1.869

2.  Early shedding of membrane-bounded ACE2 could be an indicator for disease severity in SARS-CoV-2.

Authors:  Vignesh Mariappan; Pajanivel Ranganadin; Lokesh Shanmugam; S R Rao; Agieshkumar Balakrishna Pillai
Journal:  Biochimie       Date:  2022-06-17       Impact factor: 4.372

Review 3.  Thrombosis in COVID-19.

Authors:  Thomas C Hanff; Amir M Mohareb; Jay Giri; Jordana B Cohen; Julio A Chirinos
Journal:  Am J Hematol       Date:  2020-09-16       Impact factor: 10.047

4.  Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.

Authors:  Dan Yang; Junjie Shao; Ruifeng Hu; Haimei Chen; Ping Xie; Chang Liu
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

Review 5.  Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI).

Authors:  Woon H Chong; Biplab K Saha
Journal:  Am J Med Sci       Date:  2020-10-27       Impact factor: 2.378

Review 6.  Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity.

Authors:  Maryam Eskandari Mehrabadi; Roohullah Hemmati; Amin Tashakor; Ahmad Homaei; Masoumeh Yousefzadeh; Karim Hemati; Saman Hosseinkhani
Journal:  Biomed Pharmacother       Date:  2021-02-05       Impact factor: 7.419

7.  Platelets and renal failure in the SARS-CoV-2 syndrome.

Authors:  Muhanad Taha; Dahlia Sano; Samer Hanoudi; Zahia Esber; Morvarid Elahi; Ali Gabali; Teena Chopra; Sorin Draghici; Lobelia Samavati
Journal:  Platelets       Date:  2020-09-06       Impact factor: 3.862

8.  Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Authors:  Jordana B Cohen; Thomas C Hanff; Vicente Corrales-Medina; Preethi William; Nicolas Renna; Nelson R Rosado-Santander; Juan E Rodriguez-Mori; Jonas Spaak; Jaime Andrade-Villanueva; Tara I Chang; Alejandro Barbagelata; Carlos E Alfonso; Eduardo Bernales-Salas; Johanna Coacalla; Carlos Augusto Castro-Callirgos; Karen E Tupayachi-Venero; Carola Medina; Renzo Valdivia; Mirko Villavicencio; Charles R Vasquez; Michael O Harhay; Jesse Chittams; Tiffany Sharkoski; James Brian Byrd; Daniel L Edmonston; Nancy Sweitzer; Julio A Chirinos
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-16       Impact factor: 3.738

9.  COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease.

Authors:  Rosemary Gan; Nicholas P Rosoman; David J E Henshaw; Euan P Noble; Peter Georgius; Nigel Sommerfeld
Journal:  Med Hypotheses       Date:  2020-06-23       Impact factor: 1.538

Review 10.  ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.

Authors:  Donato Zipeto; Julys da Fonseca Palmeira; Gustavo A Argañaraz; Enrique R Argañaraz
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.